Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) is scheduled to be releasing its earnings data before the market opens on Wednesday, August 7th. Analysts expect Kymera Therapeutics to post earnings of ($0.69) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.
Kymera Therapeutics Stock Performance
NASDAQ KYMR traded up $1.56 during trading on Tuesday, reaching $41.01. 185,407 shares of the company traded hands, compared to its average volume of 673,767. Kymera Therapeutics has a 1-year low of $9.60 and a 1-year high of $48.70. The company has a market cap of $2.52 billion, a price-to-earnings ratio of -16.23 and a beta of 2.22. The stock’s 50 day moving average price is $36.39 and its two-hundred day moving average price is $36.81.
Insiders Place Their Bets
In other news, insider Jared Gollob sold 23,145 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $45.81, for a total transaction of $1,060,272.45. Following the completion of the sale, the insider now owns 95,470 shares in the company, valued at $4,373,480.70. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, insider Jared Gollob sold 23,145 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $45.81, for a total transaction of $1,060,272.45. Following the completion of the sale, the insider now owns 95,470 shares in the company, valued at approximately $4,373,480.70. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Joanna Horobin sold 8,500 shares of the stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 502,345 shares of company stock valued at $19,279,932. 15.82% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Get Our Latest Analysis on Kymera Therapeutics
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Read More
- Five stocks we like better than Kymera Therapeutics
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- What Does a Stock Split Mean?
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- What is the Euro STOXX 50 Index?
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.